Reaction
Immune-Mediated Cystitis reporting signals
As of the last recalculation, Immune-Mediated Cystitis appears in 105 FAERS reports alongside 3 co-occurring drug terms. The strongest observed disproportionality signal is NIVOLUMAB (PRR 180.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nivolumab | 48 | 180.5 | 180.6 |
| Ipilimumab | 26 | 158.4 | 158.5 |
| Pembrolizumab | 43 | 136.5 | 136.6 |